The week split cleanly between evidence and headlines. Coinbase’s diversification produced the only actionable valuation-and-fundamentals combination; Lilly and ASML kept executing but still demand too much perfection, while a late batch of corporate-news claims could not be matched to primary filings. The result is one BUY, three HOLDs, and no reason to promote unverified news into a thesis.

The book

BUY

COIN — BUY

What changed this week. Coinbase entered the book at $148.47 as of the 14 August 2026 close, inside the original $145–150 entry zone. For Q2 2026 ended 30 June 2026, revenue was $1.154bn, operating income $113m, net income $359m, and diluted EPS $1.36; management said 88% of Q2 2026 net revenue came from outside bitcoin spot trading and reported a third consecutive quarter of record crypto trading-volume share. Cash and equivalents were $8.614bn at 30 June 2026. Coinbase 10-Q Q2 update Market data

That is the week’s through-line in one name: primary evidence supports a broader financial-rails business, while the price still reflects substantial crypto cyclicality. The bear case is real. A crypto drawdown can simultaneously cut asset prices, retail activity, trading volume and stablecoin balances; fee compression, lower rates, regulation, outages, custody failures and dilution can all damage per-share value. Diversification reduces dependence on bitcoin spot fees; it does not remove correlation.

The trigger to watch. A daily close above $160 after 14 August 2026 confirms the price setup. The call dies on a daily close below $135, or fundamentally after two quarters of rising industry volume with falling Coinbase share, negative adjusted EBITDA without a bounded investment programme, or non-transaction revenue falling more than 20% year over year alongside weaker USDC balances. Q2 update

Horizon. 6–12 months from 15 August 2026.

HOLD

LLY — HOLD

What changed this week. Nothing fundamental changed; the stock closed at $1,180.16 on 14 August 2026. For Q2 2026 ended 30 June 2026, revenue rose 48% year over year to $22.974bn, and Lilly raised FY2026 revenue guidance to $85–87bn and adjusted EPS guidance to $35.50–36.50. At the new close, that is roughly 32.8x the midpoint of FY2026 adjusted EPS guidance: outstanding execution, thin margin for error. Lilly 10-Q Q2 results Market data

The trigger to watch. ACCUMULATE below roughly $1,095, provided the operating thesis holds; kill the bull case if FY2026 revenue falls below $85bn absent a short supply disruption, or obesity-franchise volume growth falls below 15% year over year while net price also declines. Horizon: 12–18 months from 15 August 2026.

ASML — HOLD

What changed this week. Nothing fundamental changed, but the ADR closed at $1,844.08 on 14 August 2026, above the old $1,750 price-confirmation level. Price alone is insufficient: Q2 2026 sales were €9.3bn, and FY2026 guidance is €43–45bn of sales at a 54–56% gross margin; the next bookings evidence must validate what the valuation now assumes. Q2 results Market data

The trigger to watch. ACCUMULATE only if bookings and backlog establish double-digit FY2027 sales growth with gross margin at or above 55% and additional High-NA production qualifications. TRIM after two consecutive quarters of book-to-bill below 1 alongside leading-edge customer capex cuts. Horizon: 12–18 months from 15 August 2026.

CBZ — HOLD

What changed this week. The deal spread widened slightly: CBZ closed at $54.46 on 14 August 2026 against $55.00 cash consideration announced 29 July 2026, leaving $0.54, or 0.99% gross upside, before time and deal risk. The expected closing remains Q4 2026. Deal release Market data

The trigger to watch. Shareholder approval and regulatory clearance confirm the call; financing conditions, material regulatory resistance, a changed board recommendation, or an unexplained timetable slip kill it. Horizon: through the expected Q4 2026 closing window.

AVOID

These are research watches, not developed short theses. Each moves to action only after the claimed event is matched to a dated primary notice and the valuation, balance sheet and per-share effect are underwritten.

• INTC — AVOID. What changed: a newsletter claimed a planned $15bn equity raise became a $20bn offering to fund foundry expansion, but the 14 August 2026 review could not match it to a prospectus or filing. Trigger: a filed offering document and dilution analysis; horizon: until verified. Intel EDGAR
• LNC — AVOID. What changed: a reported CFO departure and interim appointment remained unmatched to an 8-K on 14 August 2026. Trigger: the dated filing plus updated capital guidance; horizon: through the next results cycle. Lincoln EDGAR
• META — AVOID. What changed: the Liverpool FC report concerned co-founder Eduardo Saverin personally and had no demonstrated bearing on Meta fundamentals. Trigger: none from this story; only company revenue, margins and capex can flip it. Horizon: until the next filing. Meta EDGAR
• AMZN — AVOID. What changed: a reported Bezos-linked Liverpool FC transaction was personal, unnamed-source news rather than an Amazon corporate event. Trigger: none from this story; watch AWS growth and group free cash flow. Horizon: until the next filing. Amazon EDGAR
• UCL — AVOID. What changed: a claimed TT$0.16 interim dividend, with 1 September 2026 record and 22 September 2026 payment dates, was not matched to an issuer notice. Trigger: the TTSE notice and sustainable payout coverage; horizon: through the claimed payment date. TTSE
• MJE — AVOID. What changed: a claimed J$8.66 NAV as of 11 August 2026 lacked a retrieved primary notice. Trigger: verified NAV, portfolio composition and discount-to-NAV; horizon: until the next verified NAV. JSE
• AFS — AVOID. What changed: a claimed J$0.10 dividend, record 1 September 2026 and payment 11 September 2026, remained unverified. Trigger: the issuer notice and cash-flow coverage; horizon: through the claimed payment date. JSE
• EFRESH — AVOID. What changed: a claimed general-manager appointment effective 10 August 2026 was not matched to an issuer notice. Trigger: verified appointment plus operating targets; horizon: through the next results cycle. JSE
• SIL — AVOID. What changed: a claimed US$0.000464 dividend, record 25 August 2026 and intended payment 24 September 2026, remained unverified. Trigger: the issuer notice, NAV and payout coverage; horizon: through the claimed payment date. Sterling JSE
• PTL — AVOID. What changed: a claimed lubricants-business appointment effective 3 August 2026 was not matched to an issuer notice. Trigger: verified appointment and segment-level operating improvement; horizon: through the next results cycle. Paramount JSE
• AHL — AVOID. What changed: a claimed TT$0.08 interim dividend, with 9 October 2026 record and 30 October 2026 payment dates, remained unverified. Trigger: the TTSE notice and payout coverage; horizon: through the claimed payment date. TTSE
• PJAM — AVOID. What changed: a claimed J$0.175 second interim dividend, record 7 September 2026 and payment 29 September 2026, remained unverified. Trigger: the issuer notice, NAV and cash-flow coverage; horizon: through the claimed payment date. PanJam JSE

Changed my mind

Nothing moved call category this week. COIN began and ended as BUY; LLY, ASML and CBZ remained HOLD. Holding ASML despite its 14 August 2026 close above the old price level is deliberate: the missing confirmation is bookings, not momentum.

What I’m watching next week: Coinbase’s $160/$135 levels, ASML’s next bookings commentary, Foundayo payer and uptake signals, and CBIZ’s shareholder-meeting filing.

Sources

• Coinbase Q2 10-Q
• Coinbase Q2 update
• Lilly Q2 10-Q
• Lilly Q2 results
• ASML Q2 results
• ASML High-NA
• CBIZ deal terms
• CBIZ SEC filings
• Massive market data
• SEC company search
• Jamaica Stock Exchange
• Trinidad & Tobago Exchange

Independent equity analysis, for information only, not investment advice.